Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib
Symonds, L., Linden, H., Gadi, V., Korde, L., Rodler, E., Gralow, J., Redman, M., Baker, K., Wu, V., Jenkins, I., Kurland, B., Garrison, M., Smith, J., Anderson, J., Van Haelst, C., Specht, J.Language:
english
Journal:
Clinical Breast Cancer
DOI:
10.1016/j.clbc.2018.12.008
Date:
December, 2018
File:
PDF, 2.38 MB
english, 2018
File converter
More search results
More benefits 
